<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700839</url>
  </required_header>
  <id_info>
    <org_study_id>SGLT2PCOS</org_study_id>
    <nct_id>NCT04700839</nct_id>
  </id_info>
  <brief_title>SGLT2 Inhibitors in Patients With Polycystic Ovarian Syndrome</brief_title>
  <acronym>PCOS</acronym>
  <official_title>SGLT2 Inhibitors and Metformin in Overweight/Obese Patients With Polycystic Ovarian Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai 10th People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai 10th People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Polycystic ovary syndrome (PCOS) is a common endocrine disorder, with a prevalence of 5% to&#xD;
      15% in premenopausal women. Patients with PCOS presents as abnormal menstruation, ovulation&#xD;
      disorders and/or hyperandrogenemia, and often accompanied by insulin resistance and other&#xD;
      metabolic abnormalities. Metformin has been clarified as an option in patients with PCOS.&#xD;
      However, the clinical responses to metformin are limited and different. Sodium glucose&#xD;
      co-transporter 2 (SGLT2) inhibitors are novel drugs for the treatment of type 2 diabetes,&#xD;
      with weight loss, reducing insulin resistance and cardiovascular benefits. Limited data is&#xD;
      available on the efficacy of SGLT2 inhibitors in patients with PCOS.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HOMA IR</measure>
    <time_frame>3 months</time_frame>
    <description>insulin resistance index</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anthropometry</measure>
    <time_frame>3 months</time_frame>
    <description>body mass index (kg/m2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>menstrual cycles</measure>
    <time_frame>3 months</time_frame>
    <description>menstrual frequency</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of different metabolic profiles</measure>
    <time_frame>3 months</time_frame>
    <description>fasting glucose（mmol/L)， Total cholesterol (mmol/L)(mmol/L),Triglycerides (mmol/L),HDL-c (mmol/L), LDL-c (mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of sex hormones</measure>
    <time_frame>3 months</time_frame>
    <description>total testosterone (nmol/L), testosterone (nmol/L) and SHBG (nmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabonomics</measure>
    <time_frame>3 months</time_frame>
    <description>the change of Metabonomics after the treatment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Polycystic Ovary Syndrome</condition>
  <arm_group>
    <arm_group_label>SGLT2 inhibitors group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention with SGLT2 inhibitors for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>metformin group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intervention with metformin for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SGLT2 inhibitors</intervention_name>
    <description>This isa novel drug for the treatment of type 2 diabetes, with weight loss, reducing insulin resistance and cardiovascular benefits.</description>
    <arm_group_label>SGLT2 inhibitors group</arm_group_label>
    <other_name>Canagliflozin tablets or Glucophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>metformin</description>
    <arm_group_label>metformin group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Fmale aged 18- 45;&#xD;
&#xD;
          -  Meet Rotterdam criteria;&#xD;
&#xD;
          -  Insulin Rsistance&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or have a pregnancy plan within six months; ·Congenital&#xD;
             adrenocortical hyperplasia;&#xD;
&#xD;
          -  Hyperprolactinemia;&#xD;
&#xD;
          -  Hyperthyroidism or hypothyroidism;&#xD;
&#xD;
          -  Abnormal liver function (≥ 3 times of the upper limit of normal range);&#xD;
&#xD;
          -  Abnormal renal function (GFR&lt;60ml/min/1.73m2);&#xD;
&#xD;
          -  Adrenal or ovarian tumors secreting androgens;&#xD;
&#xD;
          -  Used contraceptives, metformin, GLP-1RA, pioglitazone and contraceptives in the last 3&#xD;
             month.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shen Qu, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Shang hai Tenth People's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Tenth People' Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200072</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>August 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 7, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2021</study_first_posted>
  <last_update_submitted>January 7, 2021</last_update_submitted>
  <last_update_submitted_qc>January 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai 10th People's Hospital</investigator_affiliation>
    <investigator_full_name>Zhang Manna</investigator_full_name>
    <investigator_title>Director, Principal Investigator, Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Canagliflozin</mesh_term>
    <mesh_term>Sodium-Glucose Transporter 2 Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

